ATAI Director Granted 103,000 Options at $2.25 – Form 4 Filing

ATAI Life Sciences N.V. – Key details from Form 4 Director Amir H. Kalali filed a Form 4 on 27 June 2025 reporting the grant of a non-derivative stock option covering 103,000 common shares of ATAI Life Sciences N.V.

Rhea-AI Filing Summary

ATAI Life Sciences N.V. – Key details from Form 4

Director Amir H. Kalali filed a Form 4 on 27 June 2025 reporting the grant of a non-derivative stock option covering 103,000 common shares of ATAI Life Sciences N.V. The option was issued on 26 June 2025 with an exercise price of $2.25 per share and will vest on the earlier of (i) the day before ATAI’s next annual meeting or (ii) 26 June 2026. The option expires on 26 June 2035. After the transaction, Kalali holds 103,000 derivative securities directly. No open-market purchases or sales of ATAI shares were reported in this filing.

The filing represents a routine equity incentive award designed to align the director’s long-term interests with shareholders. Because the option is not yet exercised, there is no immediate change to share count or insider ownership of outstanding common shares.

Insights

Corporate Governance Expert

TL;DR – Routine option grant; aligns director incentives, no immediate dilution.

This Form 4 discloses a standard director compensation element: a ten-year option for 103,000 shares at $2.25, vesting within a year. Such awards are typical for growth-oriented biotech firms and aim to reinforce governance by linking board compensation to future stock performance. No shares were bought or sold, so the near-term ownership structure and market float remain unchanged. Investors should note the potential for dilution only if the share price exceeds $2.25 and the option is exercised, but the magnitude is modest relative to typical biotech option pools.

Portfolio Manager

TL;DR – Neutral event; no cash purchase, minimal signal for price direction.

From a portfolio perspective, the grant neither indicates insider bullishness (no cash outlay) nor signals distress. The $2.25 strike suggests alignment with current trading levels, but the absence of open-market buying limits its interpretive value. The filing is therefore operational, not catalytic, and does not materially alter ATAI’s investment thesis or valuation models.

Insider Trade Summary

Grant/Award: 103,000 shares

Grant/Award 1 txn

Insider Kalali Amir H

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	103,000	$0.00	$0.00

Holdings After Transaction: Stock Option — 103,000 contracts (Direct)

Footnotes (1)

1. F1. The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 26, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ATAI director Amir H. Kalali report in the latest Form 4?

He received a stock option for 103,000 ATAI common shares at an exercise price of $2.25.

When will the newly granted ATAI stock option vest?

It vests on the earlier of the day before ATAI’s next annual meeting or 26 June 2026.

Does the Form 4 show any open-market buying or selling of ATAI shares?

No. The filing only reports an equity incentive grant; no purchases or sales were disclosed.

What is the expiration date of the ATAI stock option granted to the director?

The option expires on 26 June 2035.

How many derivative securities does Amir H. Kalali own after the transaction?

He beneficially owns 103,000 derivative securities, held directly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/27/2025 - 05:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalali Amir H

(Last) (First) (Middle)

C/O ATAI LIFE SCIENCES N.V.

PROF. J.H. BAVINCKLAAN 7

(Street)

AMSTERDAM P7 1183 AT

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ATAI Life Sciences N.V. [ ATAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$2.25	06/26/2025		A		103,000		(1)	06/26/2035	Common Shares	103,000	$0	103,000	D

Explanation of Responses:

1. The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 26, 2026.

	/s/ Ryan Barrett, Attorney-in-fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.